Avelumab beim Magenkarzinom: JAVELIN Gastric 100

Avelumab for the treatment of gastric cancer: JAVELIN Gastric 100

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H (2019) Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer 7(1):30. https://doi.org/10.1186/s40425-019-0508-1

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004064.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong D, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18(5):599–610. https://doi.org/10.1016/S1470-2045(17)30240-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to PD Dr. med. Hakan Alakus.

Ethics declarations

Interessenkonflikt

M. Hartmann, F. Kütting, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hartmann, M., Kütting, F., Alakus, H. et al. Avelumab beim Magenkarzinom: JAVELIN Gastric 100. Onkologe (2021). https://doi.org/10.1007/s00761-021-00918-7

Download citation